Senseonics partners with Beta Bionics to integrate Eversense 365 CGM with iLet bionic pancreas
SENS•Senseonics partners with Beta Bionics on automated insulin delivery integration
- Senseonics entered a partnership with Beta Bionics to integrate the Eversense 365 CGM with the iLet Bionic Pancreas system.
- Integration targets an automated insulin delivery offering built around Eversense’s year-long implantable glucose sensor.
- Development work is expected to finish in Q4 2026.
- Commercial launch is planned for Q4 2026, subject to testing, validation, and regulatory requirements.
Related News
Northern Trust names Cynthia Brown president of Northern Trust Company of Delaware
NTRS•
BriaCell DSMB flags no safety issues, backs continued Phase 3 metastatic breast cancer trial of Bria-IMT plus checkpoint inhibitor
BCTX•
